Hormonal replacement therapy in menopausal women with a history of hyperprolactinemia

Hyperprolactinemia is involved in almost 30% of infertility problems. At the onset of menopause, prolactin levels often decrease; however, no data are available regarding the course of hyperprolactinemia after menopause with hormonal replacement therapy (HRT). A retrospective study was undertaken in our department to evaluate the potential role of estrogens in women with a history of hyperprolactinemia. Twenty-two patients, with hyperprolactinemia before menopause, were followed-up. Group I included 11 patients who withdrew bromocriptine treatment when menopause was confirmed. These patients were placed on HRT with no other medication administered. HRT was a combination of percutaneous estradiol gel and an oral progestin. Group II included 7 women treated by bromocriptine before menopause and after menopause concomitantly with HRT. Group III included 4 patients who did not receive HRT or other treatments once menopause was diagnosed. The mean serum prolactin level was unchanged in Group I (22.8±21.7 before and 22.8 ±16.1 ng/ml after HRT) while it increased but not significantly from 8.1 ±5.2 to 16.0±11.7 ng/ml in Group II. The mean duration of HRT was 42.8±23.8 (7–81) and 37.3±31.0 (6–99) months in Group I and II respectively. In Group III patients, PRL levels decreased spontaneously from 61.2±39.8 to 33.0±34.7 ng/ml. In conclusion, in this population of menopausal patients with a history of moderate hyperprolactinemia, HRT did not seem to affect plasma prolactin levels.